IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).

Reproducible safety and efficacy of atezolizumab plus bevacizumab for HCC in clinical practice: Results of the AB-real study

Vivaldi, Caterina;Salani, Francesca;Masi, Gianluca;
2022-01-01

Abstract

IMbrave150 has established the superiority of atezolizumab plus bevacizumab over sorafenib in patients with unresectable hepatocellular carcinoma (HCC).
2022
Fulgenzi, Claudia Angela Maria; Cheon, Jaekyung; D'Alessio, Antonio; Nishida, Naoshi; Ang, Celina; Marron, Thomas U; Wu, Linda; Saeed, Anwaar; Wietharn, Brooke; Cammarota, Antonella; Pressiani, Tiziana; Personeni, Nicola; Pinter, Matthias; Scheiner, Bernhard; Balcar, Lorenz; Napolitano, Andrea; Huang, Yi-Hsiang; Phen, Samuel; Naqash, Abdul Rafeh; Vivaldi, Caterina; Salani, Francesca; Masi, Gianluca; Bettinger, Dominik; Vogel, Arndt; Schönlein, Martin; von Felden, Johann; Schulze, Kornelius; Wege, Henning; Galle, Peter R; Kudo, Masatoshi; Rimassa, Lorenza; Singal, Amit G; Sharma, Rohini; Cortellini, Alessio; Gaillard, Vincent E; Chon, Hong Jae; Pinato, David James
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S0959804922005111-main (1).pdf

accesso aperto

Licenza: Creative commons
Dimensione 1.01 MB
Formato Adobe PDF
1.01 MB Adobe PDF Visualizza/Apri

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11568/1160215
Citazioni
  • ???jsp.display-item.citation.pmc??? 19
  • Scopus 29
  • ???jsp.display-item.citation.isi??? 27
social impact